BD Biosciences FACS Canto Flow Cytometer

BD Biosciences FACS Canto 流式细胞仪

基本信息

  • 批准号:
    7046224
  • 负责人:
  • 金额:
    $ 17.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-04-01 至 2007-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This application requests funds to purchase the BD Biosciences FACS Canto flow cytometer for the Laboratory for Cellular and Tissue Engineering (LCTE) at the University of Alabama at Birmingham. The instrument will be used to replace a 12 year old BD Biosciences FACS Sort cytometer that has required frequent servicing that at times has impacted the functioning of the laboratory. This instrumentation will allow the laboratory to continue to serve its users well into the future and to expand functionality to allow six-color flow cytometry. The LCTE is a CLIA, CAP, and FACT-compliant core facility supported by the Comprehensive Cancer Center, the Center for AIDS Research, and the Sickle Cell Center. The LCTE provides a platform for translation of promising cellular therapy (including gene-modified cellular therapy) protocols for UAB investigators. The facility provides support from the earliest level of preclinical development to the preparation of clinical grade materials and submission of INDs. Many cell products that are generated in the LCTE are prepared in a clean room environment. The current flow cytometer is located in an adjacent laboratory with a pass-through to the clean suites allowing immediate on-site analysis and consultation with the team that is preparing the graft. Since the graft engineering work often requires multiple steps with flow cytometric analysis required prior to critical decisions during processing, transport of the specimens to another facility for analysis would unnecessarily prolong the processing and potentially compromise the product. In addition, when the LCTE cytometer is not being used for cellular graft evaluation, it is available for overflow work from the Comprehensive Cancer Center, Center for AIDS Research, and the Brain Tumor SPORE NIH-funded investigators that require a 51 OK approved instrument in a CLIA-approved laboratory for their protocols. The Principal Investigator has recently been funded by the University of Alabama Health Services Foundation to undertake a major expansion of the LCTE to include protocols for somatic cell therapy, myocardial regeneration, gene therapy for sickle cell disease, dendritic cell and regulatory cell therapy for autoimmune disorders, and bone regeneration. These protocols, in addition to existing hematopoietic cell therapy and immunotherapy trials nearing approval, will substantially increase the number of users over the next two years. The laboratory will require an instrument that will serve the laboratory in the development and execution of advanced cell therapy trials.
描述(由申请人提供):本申请要求为阿拉巴马大学伯明翰分校细胞和组织工程实验室(LCTE)购买BD Biosciences FACS Canto流式细胞仪。该仪器将用于取代已有12年历史的BD Biosciences FACS Sort细胞仪,该仪器需要频繁维修,有时会影响实验室的功能。该仪器将允许实验室在未来继续为用户服务,并扩展功能以允许六色流式细胞术。LCTE是一个符合CLIA、CAP和fact标准的核心设施,由综合癌症中心、艾滋病研究中心和镰状细胞中心提供支持。LCTE为UAB研究人员提供了一个翻译有前途的细胞治疗(包括基因修饰细胞治疗)方案的平台。该设施提供从临床前开发的最早阶段到临床级材料的制备和ind的提交的支持。在LCTE中产生的许多细胞产品都是在洁净室环境中制备的。当前的流式细胞仪位于相邻的实验室,可以直通到洁净套房,可以立即进行现场分析,并与准备移植物的团队进行咨询。由于移植物工程工作通常需要多个步骤,在处理过程中的关键决策之前需要流式细胞术分析,因此将标本运送到另一个设备进行分析将不必要地延长处理时间,并可能损害产品。此外,当LCTE细胞仪不用于细胞移植评估时,它可用于综合癌症中心,艾滋病研究中心和美国国立卫生研究院资助的脑肿瘤孢子研究人员的溢出工作,这些研究人员需要在clia批准的实验室中使用51 OK批准的仪器。首席研究员最近得到了阿拉巴马大学卫生服务基金会的资助,进行了LCTE的重大扩展,包括体细胞治疗、心肌再生、镰状细胞病的基因治疗、自身免疫性疾病的树突状细胞和调节细胞治疗以及骨再生的方案。这些方案,加上现有的造血细胞治疗和免疫治疗试验即将获得批准,将在未来两年内大幅增加用户数量。该实验室将需要一个仪器,将服务于实验室的发展和执行先进的细胞治疗试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LAWRENCE S LAMB其他文献

LAWRENCE S LAMB的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LAWRENCE S LAMB', 18)}}的其他基金

Donor Innate Lymphocyte Infusion Product for Immunotherapy of Glioblastoma Multif
用于多发性胶质母细胞瘤免疫治疗的供体先天淋巴细胞输注产品
  • 批准号:
    7772397
  • 财政年份:
    2010
  • 资助金额:
    $ 17.46万
  • 项目类别:
Tissue/Pathology Core
组织/病理学核心
  • 批准号:
    7727558
  • 财政年份:
    2009
  • 资助金额:
    $ 17.46万
  • 项目类别:
Feasibility of gamma/delta T cell immunotherapy for glioblastoma
γ/δ T 细胞免疫治疗胶质母细胞瘤的可行性
  • 批准号:
    7487823
  • 财政年份:
    2007
  • 资助金额:
    $ 17.46万
  • 项目类别:
Feasibility of gamma/delta T cell immunotherapy for glioblastoma
γ/δ T 细胞免疫治疗胶质母细胞瘤的可行性
  • 批准号:
    7313172
  • 财政年份:
    2007
  • 资助金额:
    $ 17.46万
  • 项目类别:
Feasibility of gamma/delta T cell immunotherapy for glioblastoma
γ/δ T 细胞免疫治疗胶质母细胞瘤的可行性
  • 批准号:
    7869514
  • 财政年份:
    2007
  • 资助金额:
    $ 17.46万
  • 项目类别:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: AIDS
BD Biosciences FACS CANTO 流式细胞仪:艾滋病
  • 批准号:
    7335103
  • 财政年份:
    2006
  • 资助金额:
    $ 17.46万
  • 项目类别:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: SICKLE CELL DISEASE, GENE THERAPY
BD BIOSCIENCES FACS CANTO 流式细胞仪:镰状细胞病,基因治疗
  • 批准号:
    7335105
  • 财政年份:
    2006
  • 资助金额:
    $ 17.46万
  • 项目类别:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER; IMMUNOLOGY, CELL BIOLOGY
BD Biosciences FACS CANTO 流式细胞仪;
  • 批准号:
    7335107
  • 财政年份:
    2006
  • 资助金额:
    $ 17.46万
  • 项目类别:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: CANCER: MELANOMA, GLIOMA
BD Biosciences FACS CANTO 流式细胞仪:癌症:黑色素瘤、神经胶质瘤
  • 批准号:
    7335104
  • 财政年份:
    2006
  • 资助金额:
    $ 17.46万
  • 项目类别:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: MOUSE STEM CELLS: ADULT & EMBRYONIC
BD Biosciences FACS CANTO 流式细胞仪:小鼠干细胞:成人
  • 批准号:
    7335106
  • 财政年份:
    2006
  • 资助金额:
    $ 17.46万
  • 项目类别:

相似海外基金

ICF: A novel dual-target gene therapy for safe and efficacious treatment of chronic non-infectious uveitis
ICF:一种安全有效治疗慢性非感染性葡萄膜炎的新型双靶点基因疗法
  • 批准号:
    MR/Z50385X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Research Grant
Longitudinal structural and cognitive functional imaging and outcome prediction in focal epilepsy treated with gene therapy and surgical resection.
基因治疗和手术切除治疗局灶性癫痫的纵向结构和认知功能成像及结果预测。
  • 批准号:
    MR/X031039/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Research Grant
Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy
QbD 的下一代自动化和 PAT 实施以及细胞和基因治疗的增强方法
  • 批准号:
    10087446
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Collaborative R&D
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Research Grant
GeneT: The Gene Therapy CoE at the Center of Portugal
GeneT:葡萄牙中心的基因治疗 CoE
  • 批准号:
    10090933
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    EU-Funded
Developing a gene therapy product to treat pressure ulcers in lower-limb amputees
开发一种基因治疗产品来治疗下肢截肢者的压力性溃疡
  • 批准号:
    2888189
  • 财政年份:
    2023
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Studentship
Activation of long non-coding RNA by a gene therapy CRISPR/Cas9 approach to prevent vein graft failure
通过基因治疗 CRISPR/Cas9 方法激活长非编码 RNA 以预防静脉移植失败
  • 批准号:
    EP/X024563/1
  • 财政年份:
    2023
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Research Grant
SBIR Phase I: Development of an Adjustable Gene Therapy Platform Technology
SBIR 第一阶段:可调节基因治疗平台技术的开发
  • 批准号:
    2240683
  • 财政年份:
    2023
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Standard Grant
Exploration novel effects of SHED-TK-derived exosomes on TK/GCV suicide gene therapy
探索SHED-TK衍生的外泌体对TK/GCV自杀基因治疗的新作用
  • 批准号:
    23K15643
  • 财政年份:
    2023
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Gene expression profiling of skin ulcers for short-acting in vivo gene therapy
皮肤溃疡的基因表达谱用于短效体内基因治疗
  • 批准号:
    23K19673
  • 财政年份:
    2023
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了